307 related articles for article (PubMed ID: 8698629)
1. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.
Takemura Y; Kobayashi H; Miyachi H; Gibson W; Kimbell R; Jackman AL
Jpn J Cancer Res; 1996 Jul; 87(7):773-80. PubMed ID: 8698629
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.
Takemura Y; Gibson W; Kimbell R; Kobayashi H; Miyachi H; Jackman AL
J Cancer Res Clin Oncol; 1996; 122(2):109-17. PubMed ID: 8576277
[TBL] [Abstract][Full Text] [Related]
4. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
[TBL] [Abstract][Full Text] [Related]
5. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
6. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
8. Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.
Miyachi H; Takemura Y; Kobayashi H; Ando K; Ando Y
Jpn J Cancer Res; 1993 Jan; 84(1):9-12. PubMed ID: 8449831
[TBL] [Abstract][Full Text] [Related]
9. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
10. Variable expression of the folylpolyglutamate synthetase gene at the level of mRNA transcription in human leukemia cell lines sensitive, or made resistant, to various antifolate drugs.
Takemura Y; Kobayashi H; Miyachi H
Anticancer Drugs; 1999 Aug; 10(7):677-83. PubMed ID: 10507318
[TBL] [Abstract][Full Text] [Related]
11. A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).
Takemura Y; Ohnuma T; Miyachi H; Sekiguchi S
J Cancer Res Clin Oncol; 1991; 117(6):519-25. PubMed ID: 1683871
[TBL] [Abstract][Full Text] [Related]
12. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Cancer Lett; 1995 Jan; 88(1):93-9. PubMed ID: 7850779
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4- oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line.
Lu K; Yin MB; McGuire JJ; Bonmassar E; Rustum YM
Biochem Pharmacol; 1995 Jul; 50(3):391-8. PubMed ID: 7646540
[TBL] [Abstract][Full Text] [Related]
15. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
16. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
17. Enzyme studies of methotrexate-resistant human leukemic cell (K562) subclones.
Koizumi S; Allegra CJ
Leuk Res; 1992; 16(6-7):565-9. PubMed ID: 1378915
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular mechanisms of resistance to antifolate drugs: new analogues and approaches to overcome the resistance.
Takemura Y; Kobayashi H; Miyachi H
Int J Hematol; 1997 Dec; 66(4):459-77. PubMed ID: 9479873
[TBL] [Abstract][Full Text] [Related]
19. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
